Redwood City, CA, United States of America

Simon-Peter Williams

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Simon-Peter Williams: Innovator in Anti-CD8 Antibodies

Introduction

Simon-Peter Williams is a notable inventor based in Redwood City, CA. He has made significant contributions to the field of immunology through his innovative work on anti-CD8 antibodies. His research focuses on the development of antibodies that can bind to human CD8 without stimulating or inhibiting the activation of CD8 T cells.

Latest Patents

Simon-Peter Williams holds a patent for "Anti-CD8 antibodies and uses thereof." This patent includes anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8 T cells. Additionally, it encompasses nucleic acids encoding such antibodies, vectors comprising these nucleic acids, and host cells that include them. The patent also details methods for using these antibodies to detect CD8 T cells in subjects, monitor disease progress in cancer patients, and track treatment progress in individuals undergoing cancer therapy. He has 1 patent to his name.

Career Highlights

Simon-Peter Williams is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has allowed him to collaborate with other talented professionals in the field.

Collaborations

Some of his notable coworkers include Yvonne M Chen and Eugene Yu-Chuan Chiang. Their collaborative efforts contribute to the advancement of research in immunology and cancer treatment.

Conclusion

Simon-Peter Williams is a distinguished inventor whose work on anti-CD8 antibodies has the potential to impact cancer treatment significantly. His contributions to the field of immunology are noteworthy and reflect his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…